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Abstract
Driven by the longer lifespans of humans, particularly in Westernised societies, and the need to know more
about ‘healthy ageing’, ageing mice are being used increasingly in scientific research. Many departments and
institutes involved with ageing research have developed their own systems to determine intervention points
for potential refinements and to identify humane end points. Several good systems are in use, but variations
between them could contribute to poor reproducibility of the science achieved. Working with scientific and
regulatory communities in the UK, we have reviewed the clinical signs observed in ageing mice and developed
recommendations for enhanced monitoring, behaviour assessment, husbandry and veterinary interventions.
We advocate that the default time point for enhanced monitoring should be 15 months of age, unless prior
information is available. Importantly, the enhanced monitoring should cause no additional harms to the
animals. Where a mouse strain is well characterised, the onset of age-related enhanced monitoring may
be modified based on knowledge of the onset of an expected age-related clinical sign. In progeroid models
where ageing is accelerated, enhanced monitoring may need to be brought forward. Information on the
background strain must be considered, as it influences the onset of age-related clinical signs. The range
of ageing models currently used means that there will be no ‘one-size fits all’ solution. Increased awareness
of the issues will lead to more refined and consistent husbandry of ageing mice, and application of humane
end points will help to reduce the numbers of animals maintained for longer than is scientifically justified.
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The study of ageing: scientific background
Human life expectancy is increasing on a global scale.
In the UK, since 2000/2002, life expectancy in men has
increased from 75.6 to 79.2 years, and in women it has
climbed from 80.4 to 82.9 years (UK Oﬃce for
National Statistics). Increased life expectancy has
been accompanied by age distribution shifts, with
more people now older than 65 years than younger
than 15 years of age. For example, the over 65s are
projected to account for 25% of the British population
by 2046 (UK Oﬃce for National Statistics).1
This rise in the proportion of elderly people has pro-
found social and economic implications because
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healthspan – deﬁned here as the period of life free from
age-related disease – is not increasing at the same rate
as lifespan. Age is the primary risk for many highly
debilitating chronic diseases, including cardiovascular
disease, Alzheimer’s disease, osteoporosis, type 2
diabetes and many forms of cancer. Moreover, these
age-associated diseases typically co-occur with multi-
morbidity, aﬀecting an estimated 60% of people older
than 65 years of age.2 Consequently, more and more
individuals will spend a greater proportion of their lives
suﬀering poor health, and therefore there is a signiﬁ-
cant biomedical interest in advancing our understand-
ing of the ageing process. The hope is that by
identifying potential points of intervention, we can
ameliorate the ageing process, thereby extending
healthspan through the reduction in the incidence of
and/or the delaying in the onset of age-related disease.
Considerable understanding of the ageing process
has been revealed through the use of genetically tract-
able, relatively short-lived and easily maintained model
organisms such as Caenorhabditis elegans, Drosophila
melanogaster and the laboratory mouse Mus musculus.
It is now well established that a range of environmental,
pharmacological and genetic interventions extend life-
span in these organisms, and crucially these interven-
tions tend also to increase late-life health and
vitality.3–5 Furthermore, the beneﬁcial eﬀects induced
by these various interventions are generally conserved
across wide evolutionary distances, with several of them
being associated with various health beneﬁts in
humans.6 In mice, for example, it is well established
that longevity interventions such as dietary restriction
and reduced signalling through the insulin/insulin-like
growth factor 1 and mechanistic/mammalian target of
rapamycin can extend healthspan signiﬁcantly.7,8 In
addition, many of these interventions can rescue life-
span and healthspan in progeroid mouse models and in
various mouse models of disease.8,9 The information
gleaned from these types of experiments is critical if
we hope to translate the ﬁndings in mice to realistic
interventions capable of delaying the onset of multi-
morbidity in humans.2,10
To test whether a particular intervention has a bene-
ﬁcial impact on ageing, it needs to be studied in the
context of ageing (i.e. using aged individuals).11 One
important caveat when choosing to study a particular
chronological age is that profound strain and sex-spe-
ciﬁc diﬀerences exist in lifespan, healthspan and cause
of death across diﬀerent mouse strains.12 In this regard,
a valuable and freely available resource that provides
such information for a large number of mouse strains
is the Mouse Phenome Database.13 What is clear is that
there is not a ‘one-size-ﬁts-all’ scenario. The particular
age classes to be studied need to reﬂect the ageing proﬁle
of that mouse strain appropriately wherever possible.
Studying mice at diﬀerent ages, whether that be
cross-sectional approaches in diﬀerent individuals or
longitudinal approaches over the life course within
the same individual, may be necessary to determine
whether an intervention acts in an age-dependent
manner or an age-independent manner. While signiﬁ-
cant insights into the ageing process have been identi-
ﬁed using progeroid mouse models,14 these models
appear to have limitations in completely recapitulating
all aspects of ageing typically seen in conventional mice
over their lifespan. Therefore, understanding the fun-
damental mechanisms underlying ‘natural’ ageing and
deﬁning exactly how (and when) a particular interven-
tion acts to modulate age-related traits or processes
requires the use of old/aged individuals where the
mice may be ‘purposefully aged’ beyond the stage
that would be considered as the normal lifespan for
this species in commercial breeding or scientiﬁc estab-
lishments. There are many challenges associated with
maintaining cohorts of ageing mice, and the study plan
needs to take account of the potential for incidental
age-related losses.
The concept of frailty
Before discussing the various aspects of ageing, it is
important to consider a closely associated concept:
frailty.
Frailty in humans is conceptually deﬁned as a clin-
ically recognisable state of increased vulnerability to
adverse health outcomes for people of the same chrono-
logical age as a result of ageing-associated decline
across multiple physiological systems such that the abil-
ity to cope with everyday or acute stressors is severely
compromised.15 Despite much research, the biology of
frailty is not well understood, and this is partly due to
our inability to evaluate frailty in experimental models.
Therefore, the need to capture, account for and meas-
ure frailty in our ageing mouse models is not only an
ethical and welfare imperative, but also a scientiﬁc one.
Operationally, frailty in people has been deﬁned as
meeting three out of ﬁve phenotypic criteria indicating
compromised energetics: low grip strength, low energy,
slowed walking speed, low physical activity and unin-
tentional weight loss.16 The so-called frailty index (FI)
goes further by assessing the number of deﬁcits accu-
mulated over time, including disability, diseases, phys-
ical and cognitive impairments, psychosocial risk
factors and geriatric syndromes. It is proposed as a
risk index and is considered a more sensitive predictor
of adverse health outcomes.
The use of a FI in aged mice was evaluated by Parks
et al.17 using specialist equipment and invasive methods
and was found to be highly correlated to results found
in humans. This initial murine FI was modiﬁed further
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to produce a non-invasive and simpliﬁed FI using only
an eight-item assessment18 (Table 1). The results were
comparable with the more complex FI used by Parks
et al., although the ﬁner grading of frailty in the very
aged groups was not possible when using this simpliﬁed
eight-item assessment. Interestingly, the latter study18
recorded a marked increase in FI score in one mouse
immediately before its death and also found a sex dif-
ference: the FI was higher in female mice, a ﬁnding that
is consistent with studies in humans (75- to 95-year-old
cohort). FIs have been used in several subsequent stu-
dies19–22 that have reached similar conclusions, but the
focus has remained on predicting death and end points
rather than identifying intervention points for
improved care. For example, the excellent review by
Toth23 oﬀers very interesting insights as to how a com-
bination of frailty assessment with close monitoring of
bodyweight and body temperature may be used as a
predictor of death and the implementation of humane
end points.
These previous studies all show that it is potentially
feasible to develop a reliable system or index for mea-
suring frailty in ageing mice. However, we need not just
reliable measures of frailty, but also non-invasive ones
that are manageable and do not impose an unrealistic
burden on animal care staﬀ time and on resources.
Moreover, invasive or stressful measures could easily
further compromise already challenged animals by gen-
erating welfare issues that may result in a proportion of
the cohorts having to be culled earlier than necessary.
Although the risk of frailty increases with age, we
consider that its measurement in laboratory mice is not
so much an indicator of actual chronological age but
rather of the risk of adverse side eﬀects resulting from
common stressors such as handling, procedural work
and interventional behaviour assessments. A manage-
able, simpliﬁed FI assessment incorporated into the
daily or weekly welfare assessment could help predict
emerging frailty within aged cohorts, signalling the
need for increased monitoring of these vulnerable
mice. In addition, widening discussion of frailty in rela-
tion to ageing mouse studies can help raise awareness of
the need to reduce simple but common potential stres-
sors such as handling and promoting good practice (e.g.
the use of tubes or cupping rather than tails when hand-
ling mice24,25).
Clinical/phenotypic signs related to ageing
Ageing is a natural process during which structural and
functional changes accumulate in an organism as a
result of the passage of time and which eventually
lead to death. It is a multifactorial process, acting at
many levels of the organism’s physiological and func-
tional organisation, driven by genetic, epigenetic and
environmental factors.26 Precisely because of its multi-
faceted nature and causes, there is great heterogeneity
in the ageing phenotype, even among members of the
same species and even within highly inbred mouse
strains. Therefore, producing a comprehensive list of
‘typical’ signs of ageing – even in a given strain – has,
of necessity, various caveats and limitations. Moreover,
exclusively age-related changes can be diﬃcult to diﬀer-
entiate from disease, as both processes result in impair-
ment. The main diﬀerence between the two is that the
former is a normal, universal process aﬀecting all indi-
viduals, whereas the latter is an abnormal process only
aﬀecting a subset. In human clinical practice, a further
distinction is made between ageing and age-related
frailty. The distinction and what it may mean in a
laboratory animal setting – speciﬁcally in rodents – is
explored elsewhere in this document, but some of the
conclusions will necessarily overlap with those outlined
in this section. Diﬀerent mouse strains have diﬀerent
predispositions to develop one or more health condi-
tions as they grow older, and it is critical to know them
and how they may manifest themselves.12 There are
several excellent sources that can provide this sort of
information and can be supplemented with additional
data (e.g. Mouse Phenome Database; The ShARM
resource27–30).
It is also important to realise that environmental
factors can also be predictive of certain age-related con-
ditions. For example, the generalised practice of ad lib-
itum feeding of laboratory mice, coupled with a lack of
opportunity to exercise, can predispose to obesity and
obesity-related pathologies.31 Therefore, a clear know-
ledge of the animals’ past and present environment
needs to be taken into consideration as much as pos-
sible when assessing age-related health conditions.
As ageing is universally associated with a general
and progressive decline in organ systems, there are
some clinical/pathological manifestations that can be
Table 1. Eight-item simplified mouse frailty index (FI)
assessment.18
1. Coat/skin (alopecia/fur or whisker loss/dermatitis/coat
condition)
2. Musculoskeletal/physical condition (tumours/dis-
tended abdomen/gait disorders/tremor/grip strength/
body condition score)
3. Auditory function (hearing loss/balance disorders)
4. Ocular/nasal (cataracts/eye discharge or swelling/
vision loss/nasal discharge)
5. Digestive/urogenital (malocclusions/rectal, vaginal,
uterine, penile prolapse/diarrhoea)
6. Respiratory system (breathing rate/depth)
7. Discomfort (mouse grimace scale/piloerection)
8. Temperature and body weight score
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considered more or less typical in a given species or
strain. The welfare relevance of these various clinical/
pathological manifestations will depend to a large
extent on what organ(s) or system(s) are mostly aﬀected
and on how well the animal may cope or compensate
for them (see the section on frailty). Manifestations
such as hearing loss, impaired vision or generalised
hair loss do not normally cause the same level of
impairment in laboratory mice as they probably do in
their wild counterparts or indeed in humans. By con-
trast, other manifestations such as neoplasia or degen-
erative joint conditions can have profound eﬀects on
the animals’ welfare. As mice age, many conditions
develop slowly over extended periods of time, and the
body adapts to them. However, often a time is reached
such that an animal suddenly shows clinical signs
resulting from a decline in function that can no
longer be compensated (e.g. progressive heart or
kidney failure). At a cellular and tissue level, changes
lead to reductions in function, such as muscle strength,
epithelial renewal, alignment of the teeth and cardio-
vascular output. Initial signs of ageing in laboratory
mice may include thinning, texture and/or colour
change of the coat; reduced self-grooming; body-mass
change (middle-age obesity may be followed by loss of
body condition); hearing loss; deteriorating eyesight;
reduced spontaneous activity and exercise intolerance.
Individually, these changes seldom have a signiﬁcant
impact on the animals’ general well-being. However,
collectively, the animals’ decline can eventually
become noticeable and can be measured by, for exam-
ple, grip strength, endurance activity, voluntary move-
ment, speed of walking and reduced rate of wound
healing.32,33 In addition to reduced function, the inci-
dence of overtly terminal conditions (e.g. invasive
or metastatic tumours) rises dramatically with advan-
cing age.
In Table 2, we have compiled a series of clinical signs
that could be considered common of ageing in mice,
grouped according to organ or system most commonly
aﬀected. These are the types of signs that may be picked
up during the daily checking of animals that is the min-
imum legal requirement in most countries. In Table 3,
we give more details of the clinical signs to monitor,
highlight potential interventions aimed at ameliorating
or mitigating the expected adverse eﬀects and identify
clear end points enabling the scientiﬁc goals to be
achieved in a reﬁned manner. Using the information
in Table 3, the aim is that scientists and animal care
staﬀ should be able to develop a staged, progressive
enhanced monitoring and recording system based on
the age-related clinical signs identiﬁed in their particu-
lar mouse strain and study. Table 4 provides an exam-
ple of a template that could be used for enhanced
monitoring of ageing mice, with suggested monitoring
frequencies set at diﬀerent ages as a bare minimum (i.e.
even before any clinical signs appear). As those clinical
manifestations of the ageing process begin to appear
and develop, the monitoring frequencies can be
increased accordingly. We consider that adoption of
this approach should improve animal welfare by pro-
viding more reﬁned husbandry and management of
ageing mice. Further, the approach we describe can
provide research scientists with more information
about the animals they use in their studies, thus con-
tributing to the achievement of scientiﬁc goals.
Enhanced monitoring of ageing mice will yield infor-
mation which could contribute to the identiﬁcation of
subtle modulatory eﬀects of, for example, the putative
therapeutic intervention under investigation. It is recog-
nised that drug absorption, metabolism, bioavailability,
pharmacodynamics and pharmacokinetics change with
age. In some cases, this may be related to altered renal34
and/or cardiovascular function.35 It therefore seems
reasonable to suggest that subtle eﬀects in an animal
model could ultimately translate into signiﬁcant human
patient beneﬁts.
Depending on the knowledge of the particular
mouse strain, it will be possible to design a customised
monitoring regime to suit both the expected adverse
eﬀects and the scientiﬁc needs of the study. Thus, moni-
toring for age-related clinical signs may be combined
with the potential adverse eﬀects of the experiment, for
example related to lameness and swollen joints in an
experimental study of arthritis, to give a more compre-
hensive clinical monitoring and scoring system relevant
to any individual study.
Legal considerations when using ageing
rodents for scientific purposes
A ﬁnal consideration when working with ageing
rodents is the question of when exactly should the ‘pur-
poseful ageing’ of rodents be considered as requiring
authorisation under relevant legislation. What follows
is not intended to be an authoritative text on legal
requirements, since these vary between diﬀerent coun-
tries and even within the same country. Instead, we aim
to raise awareness that regulations exist and should be
complied with wherever the research is conducted. We
also attempt to describe the criteria to be considered so
as to achieve a consistent approach with regard to set-
ting the time point for commencement of enhanced
monitoring and determining when legal authorisation
may be required. We argue that the criteria for project
authorisation cannot be based solely on the age of ani-
mals. Instead, it should be based on the potential for
the animals to experience adverse eﬀects of pain, suf-
fering, distress or lasting harm (P, S, D or LH) above
the minimum threshold, as indeed enshrined by most
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laws governing the use of animals in scientiﬁc research.
In Europe, the relevant legislation is the Directive 2010/
63/EU (EUD).36 The EUD deﬁnes a ‘procedure’ as any
use, invasive or non-invasive, of an animal for
experimental or other scientiﬁc purposes, with known
or unknown outcome, or educational purposes, which
may cause the animal a level of P, S, D or LH equiva-
lent to, or higher than, that caused by the introduction
Table 2. ‘Common’ signs of ageing in mice, grouped by organ/system.
Organ/system Possible clinical signs/pathology
Skin and hair Hair thinning, hair loss, greying
Loss of vibrissae
Dry, flaky skin; unkempt coat
Delayed wound healing, greater propensity to postoperative infections/abscessation
Increased risk/incidence of cutaneous or subcutaneous tumours
Special senses Ocular opacities, loss of vision, ocular or periocular infections
Dry, sunken eye/s
Hearing loss
Loss of vibrissae
Cardiovascular General slowing down; exercise intolerance
Increased risk/incidence of:
Strokes (neurological signs; sudden death)
Heart attacks/fatal arrhythmias (extreme collapse; sudden death)
Poorer post-anaesthetic recovery/anaesthetic-related death
Respiratory Nasal discharge, sneezing, coughing/chattering, rapid/shallow breathing, dyspnoea,
aerophagia
Increased risk/incidence of tumours
Digestive Malocclusions, dental abscesses
Gastrointestinal dysfunction (diarrhoea; constipation; changed Body Condition Score39
(BCS))
Rectal prolapse
Increased risk/incidence of tumours
Musculoskeletal Arthritis/arthrosis/loss of muscle tone (swollen/painful joints; reluctance to move; gen-
eral slowing down; exercise intolerance; gait abnormalities; decreased grip strength)
Hunched posture
Increased risk/incidence of bone fractures/dislocations (pain)
Metabolic/endocrine Less able to thermoregulate (shivering; cold stress; piloerection; heat intolerance;
decreased core body temperature)
Less able to keep energy balance (weight loss; weight gain)
Less able to process/clear drugs (increased risk of toxicity)
Increased risk/incidence of tumours
Urinary Bladder dysfunction (urinary retention; incontinence)
Renal degenerative pathology (excess drinking; excess urination; weight loss)
Urethral blockages
Increased risk/incidence of tumours
Reproductive Hormonal dysfunction (abnormal oestrus cycles; permanent anoestrus; infertility)
Prolapses (penis; vagina)
Abscessation or impaction of accessory sex glands
Increased risk/incidence of dystocia
Increased risk/incidence of tumours
Vaginal discharges (may be related to benign uterine polyps)
Scrotal hernias
Neurological/behavioural Stereotypic behaviour; self-mutilation; altered consciousness or ‘temperament’
Fits/seizures (rigid tail, open-mouth, salivation)
Head tilt
Limb weakness (paresis), paralysis, ataxia; tremors; hunching
Increased risk/incidence of tumours
Clinical signs in italics denote those considered by the authors as most commonly encountered in aged mice.
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.
g
re
e
n
cl
a
y
þ
cl
ip
o
r
fi
le
n
a
il
s;
fa
tt
y
a
ci
d
su
p
p
l;
d
il
u
te
d
ch
lo
rh
e
xi
d
in
e
;
si
lv
e
r
su
lf
a
d
ia
zi
n
e
cr
e
a
m
;
d
u
st
fr
e
e
b
e
d
-
d
in
g
)
L
e
si
o
n
s
o
f
<
3
m
m
a
ff
e
ct
in
g
fa
ce
o
r
e
xt
re
m
it
ie
s;
m
o
re
e
xt
e
n
si
ve
le
si
o
n
s
o
ve
r
th
e
b
o
d
y
(0
.5
–
1
cm
)
A
s
b
e
fo
re
;
tr
y
a
d
if
fe
re
n
t
th
e
ra
p
y
fr
o
m
th
e
li
st
o
f
p
o
ss
ib
il
it
ie
s;
m
o
n
it
o
r
th
e
co
n
d
it
io
n
d
a
il
y
L
e
si
o
n
s
o
f
>
3
m
m
in
fa
ce
o
r
e
xt
re
m
it
ie
s,
e
xt
e
n
si
ve
b
o
d
y
le
si
o
n
s
a
n
d
/o
r
cl
e
a
r
d
is
co
m
fo
rt
C
o
n
si
d
e
r
la
st
re
so
rt
tr
e
a
t-
m
e
n
t(
s)
if
a
p
p
ro
p
ri
a
te
,
b
u
t
p
re
p
a
ra
ti
o
n
sh
o
u
ld
b
e
m
a
d
e
to
cu
ll
th
e
a
n
im
a
l;
m
o
n
it
o
r
d
a
il
y
N
o
cl
e
a
r
im
p
ro
ve
-
m
e
n
t
w
it
h
in
2
4
h
o
u
rs
d
e
sp
it
e
tr
e
a
tm
e
n
t
C
u
ll
G
e
n
e
ra
l
a
p
p
e
a
r-
a
n
ce
/c
o
a
t
co
n
d
it
io
n
G
re
y
h
a
ir
s
o
b
se
rv
e
d
N
o
a
ct
io
n
re
q
u
ir
e
d
G
re
y
h
a
ir
s;
sl
ig
h
tl
y
d
ir
ty
o
r
u
n
k
e
m
p
t
o
r
d
ry
p
e
lt
;
p
o
ss
ib
le
m
il
d
p
il
o
e
re
ct
io
n
E
n
su
re
a
d
e
q
u
a
te
co
m
p
a
n
-
io
n
sh
ip
to
st
im
u
la
te
a
ll
o
g
ro
o
m
in
g
;
im
p
ro
ve
g
e
n
e
ra
l
co
n
d
it
io
n
(e
.g
.
lo
w
e
r
ca
lo
ri
c
in
ta
k
e
,
m
o
re
e
xe
rc
is
e
);
if
p
il
o
e
re
ct
io
n
,i
n
ve
st
ig
a
te
fu
rt
h
e
r
(e
.g
.
h
yp
o
th
e
r-
m
ic
?)
a
n
d
re
sp
o
n
d
a
cc
o
rd
in
g
ly
G
re
y
h
a
ir
s;
u
n
k
e
m
p
t
co
a
t;
p
il
o
e
re
ct
io
n
;
st
a
in
in
g
a
ro
u
n
d
p
e
n
is
/v
a
g
in
a
A
s
b
e
fo
re
;
if
p
re
se
n
t,
tr
y
to
d
e
te
rm
in
e
ca
u
se
o
f
p
il
o
e
re
ct
io
n
a
n
d
tr
y
to
re
ct
if
y;
if
o
th
e
r
cl
in
ic
a
l
si
g
n
s
a
re
in
cr
e
a
si
n
g
in
fr
e
q
u
e
n
cy
,
m
o
n
it
o
r
d
a
il
y
p
re
p
a
re
to
cu
ll
V
e
ry
u
n
k
e
m
p
t
co
a
t
a
n
d
m
a
rk
e
d
p
il
o
e
re
ct
io
n
;
si
g
n
s
o
f
in
co
n
ti
n
e
n
ce
C
u
ll
(c
o
n
ti
n
u
e
d
)
T
a
b
le
3
.
C
o
n
ti
n
u
e
d
O
b
se
rv
a
ti
o
n
G
e
n
e
ra
l
a
ct
io
n
to
b
e
ta
k
e
n
(i
n
n
o
n
-s
h
a
d
e
d
co
lu
m
n
s)
–
in
co
n
si
d
e
ra
ti
o
n
w
it
h
th
e
P
ro
je
ct
L
ic
e
n
ce
a
d
ve
rs
e
e
ff
e
ct
s
a
n
d
h
u
m
a
n
e
e
n
d
p
o
in
ts
,
th
e
e
xp
e
ct
e
d
p
h
e
n
o
ty
p
e
o
f
th
e
a
n
im
a
l
a
n
d
th
e
n
e
e
d
s
o
f
th
e
in
te
n
d
e
d
re
se
a
rc
h
.a
G
e
n
e
ra
l
a
p
p
e
a
r-
a
n
ce
/c
o
lo
u
r
S
li
g
h
t
p
a
le
n
e
ss
n
o
te
d
in
fe
e
t
o
r
ta
il
o
r
e
ye
s
In
ve
st
ig
a
te
p
o
ss
ib
le
ca
u
se
s
a
n
d
a
ct
a
cc
o
rd
-
in
g
ly
;
lo
o
k
o
u
t
fo
r
o
th
e
r
cl
in
ic
a
l
si
g
n
s;
p
ro
vi
d
e
e
xt
ra
h
e
a
t/
n
e
st
in
g
M
o
d
e
ra
te
p
a
le
n
e
ss
A
s
b
e
fo
re
;
if
p
o
ss
ib
le
a
n
d
a
p
p
ro
p
ri
a
te
,
u
se
o
th
e
r
d
ia
g
n
o
st
ic
te
st
s
(e
.g
.
im
a
g
in
g
,
b
lo
o
d
sa
m
-
p
li
n
g
)
to
h
e
lp
d
e
te
r-
m
in
e
ca
u
se
(s
);
m
o
n
it
o
r
d
a
il
y
a
n
d
p
re
p
a
re
to
cu
ll
M
a
rk
e
d
p
a
le
n
e
ss
C
u
ll
S
p
o
n
ta
n
e
o
u
s
m
o
b
il
it
y
–
re
sp
o
n
se
to
st
im
u
li
M
in
o
r
d
e
cr
e
a
se
n
o
te
d
in
a
ct
iv
it
y
le
ve
ls
;
sl
o
w
e
r
to
re
sp
o
n
d
to
st
im
u
li
P
e
rf
o
rm
m
o
re
th
o
ro
u
g
h
e
xa
m
in
a
ti
o
n
a
n
d
a
ct
a
cc
o
rd
in
g
ly
(e
.g
.
if
a
rt
h
ri
ti
s
in
vo
lv
e
d
,
p
ro
-
vi
d
e
so
ft
e
r
o
r
d
e
e
p
e
r
b
e
d
d
in
g
;
co
n
si
d
e
r
u
se
o
f
a
n
a
lg
e
si
cs
)
M
o
re
o
b
vi
o
u
s
re
lu
c-
ta
n
ce
to
m
o
ve
w
h
e
n
ca
g
e
li
d
re
m
o
ve
d
o
r
if
p
ro
m
p
te
d
;
le
ss
a
le
rt
th
a
n
n
o
rm
a
l
A
s
b
e
fo
re
;
if
n
e
ce
ss
a
ry
a
n
d
p
o
ss
ib
le
,
ca
rr
y
o
u
t
fu
r-
th
e
r
d
ia
g
n
o
st
ic
te
st
s
(e
.g
.
im
a
g
in
g
)
to
h
e
lp
d
e
te
rm
in
e
ca
u
se
(s
);
m
o
n
it
o
r
a
t
le
a
st
w
e
e
k
ly
L
it
tl
e
vo
lu
n
ta
ry
a
ct
iv
it
y
n
o
te
d
;
is
o
la
te
d
fr
o
m
o
th
e
rs
M
o
n
it
o
r
d
a
il
y,
p
ro
vi
d
e
a
d
d
it
io
n
a
l
h
e
a
t
a
n
d
th
o
ro
u
g
h
ly
e
va
lu
a
te
a
n
y
o
th
e
r
p
o
ss
ib
le
cl
in
ic
a
l
si
g
n
s
(e
.g
.
p
a
in
?
sw
e
l-
li
n
g
s?
);
if
n
o
cl
e
a
r
ca
u
se
o
r
tr
e
a
tm
e
n
t
so
lu
ti
o
n
a
va
il
a
b
le
,
p
re
-
p
a
re
to
cu
ll
U
n
re
sp
o
n
si
ve
o
r
ve
ry
d
u
ll
o
r
cl
e
a
r
si
g
n
s
o
f
p
a
in
C
u
ll
A
b
n
o
rm
a
l
m
o
ve
m
e
n
t
S
lo
w
/s
ti
ff
P
e
rf
o
rm
m
o
re
th
o
ro
u
g
h
e
xa
m
in
a
ti
o
n
a
n
d
a
ct
a
cc
o
rd
in
g
ly
(e
.g
.
if
a
rt
h
ri
ti
s
in
vo
lv
e
d
,
p
ro
-
vi
d
e
so
ft
e
r
o
r
d
e
e
p
e
r
b
e
d
d
in
g
;
co
n
si
d
e
r
u
se
o
f
a
n
a
lg
e
si
cs
)
S
te
re
o
ty
p
y;
li
m
p
;
sl
ig
h
t
h
e
a
d
ti
lt
In
ve
st
ig
a
te
fu
rt
h
e
r
a
n
d
a
ct
a
cc
o
rd
in
g
ly
(e
.g
.
e
n
vi
r-
o
n
m
e
n
ta
l
ch
a
n
g
e
s
to
tr
e
a
t
st
e
re
o
ty
p
ic
b
e
h
a
vi
o
u
rs
)
P
a
re
si
s;
a
ta
xi
a
;
w
o
r-
se
n
in
g
o
f
so
m
e
o
f
th
e
p
re
vi
o
u
s
si
g
n
s
If
n
o
cl
e
a
r
ca
u
se
/t
re
a
t-
m
e
n
t
so
lu
ti
o
n
a
va
il
a
b
le
,
p
re
p
a
re
to
cu
ll
P
a
ra
ly
si
s,
co
m
-
p
le
te
lo
ss
o
f
li
m
b
fu
n
ct
io
n
C
u
ll
H
u
n
ch
in
g
S
li
g
h
t
h
u
n
ch
e
d
p
o
s-
tu
re
,
p
o
ss
ib
ly
in
te
rm
it
te
n
t
In
ve
st
ig
a
te
p
o
ss
ib
le
ca
u
se
s
a
n
d
a
ct
a
cc
o
rd
in
g
ly
M
o
d
e
ra
te
h
u
n
ch
e
d
p
o
st
u
re
,
p
o
ss
ib
ly
co
n
ti
n
u
o
u
s
M
o
n
it
o
r
d
a
il
y,
th
o
ro
u
g
h
ly
a
ss
e
ss
p
o
ss
ib
le
ca
u
se
s
a
n
d
o
th
e
r
cl
in
ic
a
l
si
g
n
s
a
n
d
a
ct
a
cc
o
rd
in
g
ly
;
p
re
p
a
re
to
cu
ll
M
a
rk
e
d
ly
h
u
n
ch
e
d
p
o
st
u
re
If
n
o
cl
e
a
r
ca
u
se
/t
re
a
t-
m
e
n
t
so
lu
ti
o
n
a
va
il
a
b
le
o
r
n
o
re
sp
o
n
se
to
p
re
-
vi
o
u
s
tr
e
a
tm
e
n
t,
cu
ll
G
e
n
e
ra
l
b
e
h
a
vi
o
u
r
(e
.g
.
in
te
ra
ct
io
n
w
it
h
ca
g
e
m
a
te
s/
u
se
o
f
b
e
d
d
in
g
/n
e
st
m
a
k
in
g
)
M
in
o
r
d
e
p
a
rt
u
re
fr
o
m
n
o
rm
a
l
(e
.g
.
le
ss
in
te
ra
ct
io
n
w
it
h
p
e
e
rs
;
so
m
e
n
e
g
-
le
ct
o
f
n
e
st
b
u
il
d
-
in
g
)
In
ve
st
ig
a
te
p
o
ss
ib
le
ca
u
se
s
(e
.g
.
p
a
in
?)
a
n
d
a
ct
a
cc
o
rd
in
g
ly
N
o
ti
ce
a
b
le
d
e
p
a
rt
u
re
fr
o
m
n
o
rm
a
l
(e
.g
.
b
e
co
m
in
g
is
o
la
te
d
;
m
o
re
su
b
d
u
e
d
o
r
m
o
re
a
g
g
re
ss
iv
e
)
A
s
b
e
fo
re
a
n
d
m
o
n
it
o
r
d
a
il
y
S
ig
n
if
ic
a
n
t
d
e
p
a
rt
u
re
fr
o
m
n
o
rm
a
l
If
n
o
cl
e
a
r
ca
u
se
/t
re
a
t-
m
e
n
t
so
lu
ti
o
n
a
va
il
a
b
le
,
p
re
p
a
re
to
cu
ll
U
n
re
sp
o
n
si
ve
;
ve
ry
d
u
ll
C
u
ll
P
ro
la
p
se
S
li
g
h
tl
y
p
ro
tr
u
d
in
g
p
e
n
is
,
va
g
in
a
o
r
re
ct
u
m
C
o
n
si
d
e
r
p
o
ss
ib
le
tr
e
a
t-
m
e
n
t/
s
w
it
h
E
V
M
o
re
p
ro
n
o
u
n
ce
d
p
ro
tr
u
si
o
n
A
s
b
e
fo
re
if
a
p
p
ro
p
ri
a
te
;
o
th
e
rw
is
e
co
n
si
d
e
r
te
rm
in
a
ti
o
n
N
o
re
so
lu
ti
o
n
d
e
sp
it
e
tr
e
a
tm
e
n
t/
s;
d
a
m
a
g
e
d
o
rg
a
n
s
C
u
ll
(c
o
n
ti
n
u
e
d
)
T
a
b
le
3
.
C
o
n
ti
n
u
e
d
O
b
se
rv
a
ti
o
n
G
e
n
e
ra
l
a
ct
io
n
to
b
e
ta
k
e
n
(i
n
n
o
n
-s
h
a
d
e
d
co
lu
m
n
s)
–
in
co
n
si
d
e
ra
ti
o
n
w
it
h
th
e
P
ro
je
ct
L
ic
e
n
ce
a
d
ve
rs
e
e
ff
e
ct
s
a
n
d
h
u
m
a
n
e
e
n
d
p
o
in
ts
,
th
e
e
xp
e
ct
e
d
p
h
e
n
o
ty
p
e
o
f
th
e
a
n
im
a
l
a
n
d
th
e
n
e
e
d
s
o
f
th
e
in
te
n
d
e
d
re
se
a
rc
h
.a
E
xt
e
rn
a
l
lu
m
p
s/
m
a
ss
e
s
S
m
a
ll
lu
m
p
s/
m
a
ss
e
s
n
o
t
a
ff
e
ct
in
g
n
o
rm
a
l
b
o
d
y
fu
n
ct
io
n
s
C
o
n
si
d
e
r
p
o
ss
ib
le
tr
e
a
t-
m
e
n
t/
s
w
it
h
E
V
if
a
p
p
ro
p
ri
a
te
M
e
d
iu
m
-s
iz
e
(0
.5
–
0
.8
cm
)
lu
m
p
s/
m
a
ss
e
s
A
s
b
e
fo
re
;
ch
e
ck
fo
r
p
o
s-
si
b
le
p
re
se
n
ce
o
f
o
th
e
r
in
te
rn
a
l
lu
m
p
s
a
n
d
/o
r
o
th
e
r
cl
in
ic
a
l
si
g
n
s;
m
o
n
it
o
r
b
o
d
y
co
n
d
it
io
n
sc
o
re
w
e
e
k
ly
L
a
rg
e
lu
m
p
s
(0
.8
–
1
cm
);
u
lc
e
ra
te
d
o
r
in
fe
ct
e
d
If
n
o
cl
e
a
r
ca
u
se
/t
re
a
t-
m
e
n
t
so
lu
ti
o
n
a
va
il
a
b
le
,
p
re
p
a
re
to
cu
ll
L
u
m
p
s/
m
a
s-
se
s
>
1
.1
cm
o
r
a
ff
e
ct
in
g
b
o
d
y
fu
n
ct
io
n
s
/
m
o
b
il
it
y
C
u
ll
In
te
rn
a
l
lu
m
p
s/
m
a
ss
e
s
(i
m
p
a
ct
e
d
se
m
in
a
l
ve
si
-
cl
e
s
ca
n
b
e
co
m
e
q
u
it
e
la
rg
e
a
n
d
ye
t
ca
u
se
n
o
a
p
p
a
re
n
t
il
l-
e
ff
e
ct
s)
S
m
a
ll
p
a
lp
a
b
le
lu
m
p
s/
m
a
ss
e
s
n
o
t
a
ff
e
ct
-
in
g
n
o
rm
a
l
b
o
d
y
fu
n
ct
io
n
s
C
o
n
si
d
e
r
p
o
ss
ib
le
tr
e
a
t-
m
e
n
t/
s
w
it
h
E
V
if
a
p
p
ro
p
ri
a
te
;
ch
e
ck
fo
r
o
th
e
r
p
o
ss
ib
le
cl
in
ic
a
l
si
g
n
s
M
e
d
iu
m
-s
iz
e
(<
0
.5
cm
)
lu
m
p
s/
m
a
ss
e
s
A
s
b
e
fo
re
;
co
n
si
d
e
r
th
e
p
o
ss
ib
le
u
se
o
f
o
th
e
r
d
ia
g
n
o
st
ic
te
st
s
(e
.g
.
u
lt
ra
so
u
n
d
im
a
g
in
g
);
m
o
n
it
o
r
b
o
d
y
co
n
d
it
io
n
sc
o
re
w
e
e
k
ly
L
a
rg
e
lu
m
p
s
(>
0
.5
cm
);
co
n
cu
r-
re
n
t
p
re
se
n
ce
o
f
o
th
e
r
cl
in
ic
a
l
si
g
n
s
(e
.g
.
p
a
ll
o
r)
If
n
o
cl
e
a
r
ca
u
se
/t
re
a
t-
m
e
n
t
so
lu
ti
o
n
a
va
il
a
b
le
,
p
re
p
a
re
to
cu
ll
L
a
rg
e
lu
m
p
s/
m
a
ss
e
s
a
ff
e
ct
-
in
g
b
o
d
y
fu
n
c-
ti
o
n
s
o
r
ca
u
si
n
g
o
th
e
r
si
g
n
if
i-
ca
n
t
cl
in
ic
a
l
si
g
n
s
C
u
ll
E
ye
d
e
fe
ct
s
D
e
fe
ct
s
u
n
li
k
e
ly
to
a
ff
e
ct
n
o
rm
a
l
b
o
d
y
fu
n
ct
io
n
s
a
n
d
b
e
h
a
v-
io
u
r
(e
.g
.
ca
ta
ra
ct
s,
o
n
e
m
is
si
n
g
e
ye
,
co
n
-
ju
n
ct
iv
it
is
,
sm
a
ll
e
ye
)
C
o
n
si
d
e
r
p
o
ss
ib
le
tr
e
a
t-
m
e
n
t(
s)
w
it
h
E
V
if
a
p
p
ro
p
ri
a
te
;
ch
e
ck
fo
r
p
o
ss
ib
le
b
e
h
a
vi
o
u
ra
l
ch
a
n
g
e
s
o
r
o
th
e
r
cl
in
-
ic
a
l
si
g
n
s
D
e
fe
ct
s
li
k
e
ly
to
re
su
lt
in
p
a
in
o
r
a
ff
e
ct
n
o
rm
a
l
b
o
d
y
fu
n
c-
ti
o
n
s
(e
.g
.
sw
o
ll
e
n
,
cl
o
se
d
e
ye
;
p
ro
-
tr
u
d
in
g
e
ye
)
M
o
n
it
o
r
d
a
il
y
D
e
fe
ct
s
cl
e
a
rl
y
a
ff
e
ct
-
in
g
n
o
rm
a
l
b
o
d
y
fu
n
ct
io
n
s
o
r
b
e
h
a
v-
io
u
r
(e
.g
.
u
lc
e
ra
ti
o
n
)
If
n
o
cl
e
a
r
ca
u
se
/t
re
a
t-
m
e
n
t
so
lu
ti
o
n
a
va
il
a
b
le
o
r
n
o
re
sp
o
n
se
to
p
re
-
vi
o
u
s
tr
e
a
tm
e
n
t,
cu
ll
S
ig
n
s
o
f
p
a
in
th
a
t
ca
n
n
o
t
b
e
co
n
tr
o
ll
e
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of a needle in accordance with good veterinary practice.
Keeping animals alive, for a qualifying scientiﬁc pur-
pose, beyond this point would require project author-
isation. This is important because procedures can only
be applied to a protected animal as part of a programme
of work described in a project authorisation.
Where the scientiﬁc investigation relates to the
physiological process of ageing, or alternatively because
there is a requirement to investigate a disease mechan-
ism or metabolism of a drug in an ageing animal, per-
haps to mimic the human condition more accurately,
then keeping mice beyond the age when they would nor-
mally be kept in standard eﬃcient breeding programs
will be necessary in order to achieve the scientiﬁc goals.
There are currently many thousands of mice in regular
use in scientiﬁc studies globally. These include non-
genetically altered, wild-type, in-bred and genetically
altered (GA; where the genetic alteration may have
been either created experimentally or occurs naturally
and is potentially expected to be associated with a harm-
ful phenotype). Some of these are very well charac-
terised both genetically and phenotypically, others less
so, particularly the phenotypes of ageing strains. Both in
EU and the UK, all mice kept for use in scientiﬁc pro-
cedures are protected animals irrespective of whether
they carry a genetic alteration. In the UK, the breeding
and maintenance of virtually all GA mice, irrespective
of whether they have a harmful clinical phenotype asso-
ciated with the genetic alteration, requires project
authorisation. This is because it is assumed that all
experimentally created mouse strains may cross the
threshold requiring project authorisation, and few wel-
fare assessments (as deﬁned and required under the
EUD) have been completed on established strains with
the aim of demonstrating that they do not have a harm-
ful clinical phenotype that may have an impact. Across
EU member states, the EUD has been interpreted dif-
ferently: in some member states, whilst all laboratory-
Table 4. Example of an enhanced monitoring sheet
Date Weight
(measure
fortnightly
unless on a
downward
trajectory)
Note the %
weight
loss from
15-month
starting point
Note all observations:
Weight
Coat condition
General appearance/colour
Mobility/movement/hunching
General behaviour (e.g. interaction with cage
mates/use of bedding/nest making)
Genitals
External and internal lumps/masses
Eye defects
Respiration
Stools
(Check Table 3 for advice to follow)
Note action taken
NB. Commence enhanced health check, score and weigh ageing animals (unless there is information to suggest otherwise) from 15
months of age on a fortnightly basis. This frequency should be increased if the animal gives any cause for concern. Moreover, there is
some evidence to suggest that weekly monitoring after the animals’ reach 20 months of age is recommended – at least in some strains –
as there can be a steep downward trend in their health. After 30 months of age, it is likely that fewer animals will remain alive and that
they may require daily enhanced monitoring.
The above monitoring frequencies are only a broad recommendation. As you gather more information on your mouse strains, frequencies
may be altered to suit your local needs. Monitoring frequency can be influenced by many factors including – but not limited to – the
animals’ immediate housing environment (e.g., cage type), strain and genetic background of mice, gender, disease model and study
needs.
Table 3 lists a number of changes that can be associated with the ageing process, together with suggestions as to how to monitor and/or
act upon them. As observed changes accumulate or increase in ‘intensity’, so the frequency of monitoring increases in proportion. It is
important to emphasize that there is no perfect tabulated list of clinical signs that can cover all the various possible pathological
conditions that animals may develop as they age. In addition, local practices and experience, together with any limitations that may
be described in associated project authorization and study design, will necessarily affect the way these conditions are assessed and acted
upon.
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created strains are produced under project authorisa-
tion, only GA mice with a manifest adverse phenotype
require project authorisation, the assumption being that
there is no overt harm unless it has been previously
demonstrated. This situation has recently been reviewed
by the EU Commission and no substantive changes are
anticipated. Because of this diﬀerence between EU
member states, some GA mice will already be under
project authorisation and others not.
What about mice that are ‘purposefully aged’? Does
the ‘purposeful ageing’ of the animals, in itself, require
project authorisation, as deﬁned above? Should consid-
eration be given to the eﬀect – enhancement or dimin-
ishment – of the genetic alteration on the ageing
process? Will they have diﬀerent or additional adverse
clinical eﬀects as a consequence of the ageing process
that may need to be deﬁned in a project authorisation?
As stated above, we consider that the requirement
for project authorisation of ageing animals cannot be
determined solely on age but should be viewed as a
performance standard when any P, S, D or LH mani-
fests as ageing-associated clinical signs and has a detri-
mental impact on the animal and the animal is not
immediately culled. This is consistent with the deﬁn-
ition of a procedure for scientiﬁc purpose (see above).
Given that there is already published evidence of age-
related ‘watersheds’ in some mouse colonies,37 when no
information is available from establishment health rec-
ords or from the published literature on a particular
mouse strain or new genotype, then we consider it rea-
sonable to propose that there should be a point for
enhanced monitoring of any ageing mice. Working
with the scientiﬁc and regulatory communities in the
UK, comprised of a wide range of scientists and experi-
enced animal care technologists caring for large colo-
nies of aged mice used for diﬀerent purposes, we
propose that this age-related trigger point for enhanced
monitoring should be 15 months. From this age
onwards, mice should undergo an enhanced regime of
monitoring with additional husbandry or veterinary
intervention steps aimed at identifying, recording and
mitigating any ageing-associated adverse clinical signs.
This general recommendation does not preclude the
establishment of earlier points for enhanced monitoring
when this is seen as a prudent decision, such as when
expected progeroid mouse models are generated or
when new GA models start showing signs of frailty or
ageing earlier than expected.
Where there is information available on the phenotype
of the mouse and the strain is already well characterised,
with details available through, for example, the Mouse
Passport Scheme,38 establishment health records or pub-
lished literature, then the trigger point for enhanced
monitoring and consideration given to project authorisa-
tion should coincide with the onset of any known adverse
ageing-associated clinical or phenotypic sign(s).
Obviously, this timing – for both enhanced monitoring
and project authorisation – can vary widely, depending
on the onset of expected age-related clinical or phenotypic
sign(s) in mice of that particular strain and need not coin-
cide with the 15-month trigger point mentioned above.
Consideration of project authorisation will involve a
harm–beneﬁt analysis (HBA) weighing the potential
ageing-related harms that the animal is expected to
experience against the potential scientiﬁc beneﬁts. Such
a HBA will need to be conducted on a study-by-study
basis, relying on sound information about the scientiﬁc
objectives, the likelihood of achieving them, their beneﬁ-
cial impact, the potential welfare implications, their miti-
gation and so on.
In all cases, information on the background strain
must be taken into account, as this is known to have an
inﬂuence on the onset of age-related clinical signs. For
instance, the question may be asked whether it is neces-
sary to implement enhanced monitoring of mice from
15 months of age where no adverse phenotype is
expected. We are of the opinion that if there is evidence
(e.g. from health records) to show that no adverse clin-
ical or phenotypic signs are expected, then an informed
decision can be taken that there is no need for enhanced
monitoring because no signs of P, S, D or LH are
anticipated. For example:
1. It is intended to maintain a well-known and well-
characterised wild-type strain of mouse with no gen-
etic alteration for up to 24 months for a study on
ageing. The evidence from many years of health rec-
ords shows that these mice do not display any
adverse clinical signs before 18 months of age. The
researcher intends to kill the mice humanely as soon
as the ﬁrst clinical signs of ageing are observed.
Therefore, in this case, the P, S, D or LH trigger
point for enhanced monitoring would be reached
when the mice became 18 months old. As the
researcher does not intend to maintain the mice
beyond the point where they develop adverse clinical
signs, project authorisation would not be required.
2. A GA mouse strain is already bred under project
authority because it carries a genetic alteration asso-
ciated with a phenotype featuring reduced lifespan.
The genetic alteration is known to induce premature
ageing, and the mice are expected to display age-
related clinical signs from six months onwards. If
the intention is to keep these animals alive beyond
six months of age, then they should be subject to
enhanced monitoring against a predetermined set of
criteria and at an agreed frequency from just before
this age, for example ﬁve months, to minimise adverse
eﬀects experienced by the mice and potentially reﬁne
the model.
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Conclusions
Human lifespan is increasing globally, whereas health-
span – the period of life free from age-related diseases –
is not increasing at the same rate. One consequence is
the fact that we are witnessing a concerted research
eﬀort into the causes of ageing and the control of its
consequences, and this global eﬀort has resulted in a
marked increase in the number of research groups that
use ageing rodents – particularly mice – that are ‘pur-
posefully aged’ beyond the stage that would be con-
sidered normal in commercial breeding or scientiﬁc
establishments. Hence, there is an urgent need to
ensure that the husbandry and management of these
ageing animals is approached in a consistent way,
thereby optimising their welfare and, at the same
time, underpinning the achievement of good quality,
reproducible scientiﬁc results.
An obstacle for optimising the welfare of ageing
rodents is the fact that age and frailty-related health
problems and their manifestations can vary signiﬁcantly,
depending on a range of factors, including genotype, sex,
housing and environment. The interface between ageing
and frailty itself is complex and not easy to tease apart.
For models of accelerated ageing using GA animals, for
example, it could prove particularly helpful to include
the signs of frailty in any enhanced monitoring regime
by combining parameters from the various tables pre-
sented. Clearly, there is a signiﬁcant advantage to animal
welfare through identiﬁcation and application of extra
vigilance for those animals identiﬁed as frail by the scor-
ing criteria. As mentioned previously, there is no ‘one-
size-ﬁts-all’ answer, and the monitoring and interven-
tions need to be tailored to the mouse strain, study
design and scientiﬁc objectives without causing add-
itional harms to the animals and without being too
labour intensive.
We believe that a signiﬁcant way forward towards
the achievement of improved animal welfare and better
science is the adoption of enhanced clinical monitoring
of ageing mouse colonies intended for scientiﬁc use.
Working with the scientiﬁc and regulatory communities
in the UK, we advocate that such an enhanced moni-
toring regime is adopted from (a) the expected onset of
one or more age-related adverse clinical signs where the
mouse (wild type or GA) is well characterised, (b) an
age-related time point of 15 months where no informa-
tion is yet available to suggest that there will be adverse
age-related clinical signs prior to this time, or (c) a
combination of these parameters.
There is no provision within current EU legislation
to ascribe an age-related ‘engineering’ threshold to
regulation. Instead, the threshold is based on the per-
formance standard related to the potential of any
procedure – including purposeful ageing – to have the
eﬀect of causing the animal a level of pain, suﬀering,
distress or lasting harm equivalent to, or higher than,
that caused by the introduction of a needle in accord-
ance with good veterinary practice. Accordingly,
throughout this paper, we have described a trigger
point for enhanced monitoring based not solely on
the age of the animals, but also on the likelihood of
clinical signs being evident at a particular age. This
will also assist in determining whether and when legal
authorisation is required for particular strains.
As a ﬁrst step to addressing the enhanced monitor-
ing of ageing animals, this paper has focused through-
out on mice, as this is the most commonly used species
in scientiﬁc research in Europe, accounting for 61% of
all of the animals used in scientiﬁc procedures in
Europe in 2017. However, the principles described
herein are applicable to other species and other scien-
tiﬁc ﬁelds. By raising awareness of the issues around the
use of ageing mice and the adoption of staged, progres-
sive monitoring systems, we aim to improve the welfare
of ageing mice kept for scientiﬁc purposes and conse-
quently reﬁne the research models that use them.
The above monitoring frequencies are only a broad
recommendation. As you gather more information on
your mouse strains, frequencies may be altered to suit
your local needs. Monitoring frequency can be inﬂu-
enced by many factors, including but not limited to
the animals’ immediate housing environment (e.g.
cage type), strain and genetic background of mice,
sex, disease model and study needs.
Table 3 lists a number of changes that can be asso-
ciated with the ageing process, together with sugges-
tions as to how to monitor and/or act upon them. As
observed changes accumulate or increase in ‘intensity’,
so the frequency of monitoring increases in proportion.
It is important to emphasise that there is no perfect
tabulated list of clinical signs that can cover all the
various possible pathological conditions that animals
may develop as they age. In addition, local practices
and experience, together with any limitations that
may be described in associated project authorisation
and study design, will necessarily aﬀect the way these
conditions are assessed and acted upon.
Declaration of Conflicting Interests
The author(s) declared no potential conﬂicts of interest with
respect to the research, authorship and/or publication of this
article.
Funding
The author(s) received no ﬁnancial support for the research,
authorship and/or publication of this article.
Wilkinson et al. 11
ORCID iD
Michael JA Wilkinson https://orcid.org/0000-0002-4212-
2108
J Norman Flynn https://orcid.org/0000-0003-0167-5109
References
1. Office for National Statistics. Health and life expectan-
cies, https://www.ons.gov.uk/peoplepopulationandcom-
munity/healthandsocialcare/healthandlifeexpectancies
(accessed December 2018).
2. Figueira I, Fernandes A, Mladenovic Djordjevic A, et al.
Interventions for age-related diseases: shifting the para-
digm. Mech Ageing Dev 2016; 160: 69–92.
3. Gems D and Partridge L. Genetics of longevity in model
organisms: debates and paradigm shifts. Annu Rev
Physiol 2013; 75: 621–444.
4. Fontana L and Partridge L. Promoting health and lon-
gevity through diet: from model organisms to humans.
Cell 2015; 161: 106–118.
5. Selman C and Withers DJ. Mammalian models of
extended healthy lifespan. Philos Trans R Soc Lond B
Biol Sci 2011; 366: 99–107.
6. Most J, Tosti V, Redman LM, et al. Calorie restriction in
humans: an update. Ageing Res Rev 2017; 39: 36–45.
7. Mannick JB, Morris M, Hockey HP, et al. TORC1 inhib-
ition enhances immune function and reduces infections in
the elderly. Sci Transl Med 2018; 11: 449.
8. Ramos FJ, Chen SC, Garelick MG, et al. Rapamycin
reverses elevated mTORC1 signaling in lamin A/C-defi-
cient mice, rescues cardiac and skeletal muscle function,
and extends survival. Sci Transl Med 2012; 4: 144ra103.
9. Halagappa VK, Guo Z, Pearson M, et al. Intermittent
fasting and caloric restriction ameliorate age-related
behavioral deficits in the triple-transgenic mouse model
of Alzheimer’s disease. Neurobiol Dis 2007; 26: 212–220.
10. Longo VD, Antebi A, Bartke A, et al. Interventions to
slow aging in humans: are we ready? Aging Cell 2015; 14:
497–510.
11. Selman C, Lingard S, Choudhury AI, et al. Evidence for
lifespan extension and delayed age-related biomarkers in
insulin receptor substrate 1 null mice. FASEB J 2008; 22:
807–818.
12. Selman C and Swindell WR. Putting a strain on diversity.
EMBO J 2018; 37.
13. The Jackson Laboratory. Mouse Phenome Database,
https://phenome.jax.org/ (accessed July 2019).
14. Liao CY and Kennedy BK. Mouse models and aging:
longevity and progeria. Curr Top Dev Biol 2014; 109:
249–285.
15. Chen X, Mao G and Leng SX. Frailty syndrome: an
overview. Clin Interv Aging 2014; 9: 433–441.
16. Fried LP, Tangen CM, Walston J, et al. Frailty in older
adults: evidence for a phenotype. J Gerontol A Biol Sci
Med Sci 2001; 56: M146–M156.
17. Parks RJ, Fares E, MacDonald JK, et al. A procedure for
creating a frailty index based on deficit accumulation in
ageing mice. J Gerontol A Biol Sci Med Sci 2012; 67:
217–227.
18. Whitehead JC, Hildebrand BA, Sun M, et al. A clinical
frailty index in ageing mice: comparisons with frailty
index data in humans. J Gerontol A Biol Sci Med Sci
2014; 69: 621–632.
19. Rockwood K, Blodgett JM, Theou O, et al. A frailty
index based on deficit accumulation quantifies mortality
risk in humans and mice. Sci Rep 2017; 7: 43068.
20. Jansen JH, Moghtadaei M, Mackasey M, et al. Atrial
structure, function and arrhythmogenesis in aged and
frail mice. Sci Rep 2017; 7: 44336.
21. Feridooni HA, Sun MH, Rockwood K, et al. Reliability
of a frailty index on the clinical assessment of health
benefits in male C57BL/J6 mice. J Gerontol A Biol Sci
Med Sci 2015; 70: 686–693.
22. Kane AE and Howlett SE. Approaches to the assessment
of frailty in animal models. In: Ram JL and Conn PM
(eds) Conn’s handbook of models for human aging. 2nd ed.
London: Academic Press/Elsevier, 2018, pp.551–561.
23. Toth L. Identifying and implementing endpoints for geri-
atric mice. Comp Med 2018; 68: 439–451.
24. Hurst JL and West RS. Taming anxiety in laboratory
mice. Nat Methods 2010; 7: 825–826.
25. National Centre for the Replacement, Refinement &
Reduction of Animals in Research. How to pick up a
mouse, https://www.nc3rs.org.uk/how-to-pick-up-a-mouse
(accessed July 2019).
26. Jayanthi P, Joshua E and Ranganathan K. Ageing and
its implications. J Oral Maxillofac Pathol 2010; 14:
48–51.
27. Brayton CF, Treuting PM and Ward JM. Pathobiology
of ageing mice and GEM: background strains and experi-
mental design. Vet Pathol 2012; 49: 85–105.
28. Yuan R, Tsaih SW, Petkova SB, et al. Aging in inbred
strains of mice: study design and interim report on
median lifespans and circulating IGF1 levels. Aging Cell
2009; 8: 277–287.
29. Pettan-Brewer C and Treuting PM. Practical pathology
in aging mice. Pathobiol Aging Age Relat Dis 2011; 1:
7202.
30. Taylor I. Mouse. In: McIness EF (ed) Background lesions
in laboratory animals: a color atlas. Edinburgh, UK:
Saunders, Elsevier, 2012, pp.45–72.
31. Martin B, Ji S, Maudsley S, et al. ‘Control’ laboratory
rodents are metabolically morbid: why it matters. Proc
Natl Acad Sci U S A 2010; 107: 6127–6133.
32. Liu H, Graber TG, Ferguson-Stegall L, et al. Clinically
relevant frailty index for mice. J Gerontol A Biol Sci Med
Sci 2014; 69: 1485–1491.
33. Mimeault M and Batra SK. Recent advances on skin-
resident stem/progenitor cell functions in skin regener-
ation, aging and cancers and novel anti-aging and
cancer therapies. J Cell Mol Med 2010; 14: 116–134.
34. Aymanns C, Keller F, Maus S, et al. Review of the
pharmacokinetics and pharmacodynamics and the aging
kidney. Clin J Am Soc Nephrol 2010; 5: 314–327.
35. Sera LC and McPherson ML. Pharmacokinetics and
pharmacodynamic changes associated with aging and
implications for drug therapy. Clin Geriatr Med 2012;
28: 273–286.
12 Laboratory Animals 0(0)
36. EUD. European Directive 2010/63/EU of the European
Parliament and of the Council on the protection of animals
used for scientific purposes, https://eur-lex.europa.eu/
legal-content/EN/TXT/?uri¼celex%3A32010L0063
(accessed July 2019).
37. Kitching A. A retrospective review of the causes of deaths
in an aged mouse colony. Poster presentation. IAT
Congress, Harrogate, UK, 2018.
38. RSPCA. https://science.rspca.org.uk/sciencegroup/
researchanimals/implementing3rs/biotechnology
(accessed July 2019).
39. Ullman-Cullere´ MH and Foltz CJ. Body condition scor-
ing: a rapid and accurate method for assessing health
status in mice. Lab Anim Sci 1999; 49: 319–323.
Re´sume´
Du fait de la dure´e de vie accrue des humains, en particulier dans les socie´te´s occidentalise´es, et du besoin
d’en savoir plus sur «le vieillissement en bonne sante´», les souris vieillissantes sont de plus en plus utilise´es
dans la recherche scientifique. De nombreux services et instituts implique´s dans la recherche sur le vieil-
lissement ont e´labore´ leurs propres syste`mes afin de de´terminer les points d’intervention permettant des
ame´liorations et d’identifier des crite`res e´thiquement acceptables. Plusieurs bons syste`mes sont en cours
d’utilisation mais les variations qui existent entre eux pourraient contribuer a` une mauvaise reproductibilite´
de la science en de´coulant. En travaillant avec les communaute´s scientifiques et re´glementaires au
Royaume-Uni, nous avons examine´ les signes cliniques observe´s chez les souris vieillissantes et e´labore´
des recommandations pour ame´liorer les interventions de surveillance, d’e´valuation du comportement,
d’e´levage et de soins ve´te´rinaires. Nous pre´conisons que la mise en place d’une surveillance accrue ait
lieu, par de´faut, lorsque les souris atteignent l’aˆge de 15 mois, a` moins que des informations ante´rieures
ne soient disponibles. Fait important, l’ame´lioration de la surveillance ne doit pas causer d’autres pre´judices
aux animaux. Lorsqu’une souche de souris est bien caracte´rise´e, le de´marrage de la surveillance accrue lie´e
a` l’aˆge peut eˆtre modifie´ en fonction des connaissances a` disposition sur l’apparition d’un signe clinique
attendu lie´ a` l’aˆge. Dans les mode`les proge´roı¨des ou` le vieillissement est acce´le´re´, la surveillance accrue
peut ne´cessiter de de´marrer plus toˆt. Les informations sur l’historique de la souche doivent eˆtre prises en
compte car elles influencent l’apparition des signes cliniques lie´s a` l’aˆge. La gamme des mode`les de vieil-
lissement utilise´s actuellement signifie qu’il n’y a pas de solution universelle de type «taille unique». Une
sensibilisation accrue aux proble`mes permettra un e´levage plus raffine´ et cohe´rent des souris vieillissantes
et l’application de crite`res humains qui contribueront a` re´duire le nombre d’animaux conserve´s pendant plus
longtemps que scientifiquement justifie´.
Abstract
Im Zusammenhang mit der la¨ngeren Lebenserwartung des Menschen, insbesondere in westlichen
Gesellschaften, und der Notwendigkeit, mehr u¨ber Ðgesundes Altern‘‘ zu erforschen, werden in der
Wissenschaft zunehmend alternde Ma¨use eingesetzt. Viele Einrichtungen, die sich mit der
Alterungsforschung befassen, haben eigene Systeme entwickelt, um Interventionspunkte fu¨r potenzielle
Verfeinerungen zu bestimmen und humane Endpunkte zu identifizieren. Mehrere gute Systeme sind im
Einsatz, doch die zwischen ihnen bestehenden Variationen bewirken unter Umsta¨nden eine schlechte
Reproduzierbarkeit der erreichten Forschungsergebnisse. In Zusammenarbeit mit Wissenschaftlern und
Aufsichtsbeho¨rden in Großbritannien haben wir die klinischen Anzeichen bei alternden Ma¨usen untersucht
und Empfehlungen fu¨r eine verbesserte U¨berwachung, Verhaltensbewertung, Haltung und tiera¨rztliche
Maßnahmen entwickelt. Wir empfehlen, dass der Standardzeitraum fu¨r eine versta¨rkte U¨berwachung
15 Monate betragen sollte, sofern keine Vorabinformationen vorliegen. Wichtig ist, dass die versta¨rkte
U¨berwachung keine zusa¨tzlichen Belastungen fu¨r die Tiere verursacht. Bei gut charakterisierten
Maussta¨mmen kann der Beginn der altersbedingten versta¨rkten U¨berwachung basierend auf der jeweiligen
Kenntnis des Beginns eines erwarteten altersbedingten klinischen Zeichens modifiziert werden. Bei
Progeroidmodellen, bei denen die Alterung beschleunigt wird, muss eine verbesserte U¨berwachung eventuell
vorverlegt werden. Informationen u¨ber die Hintergrundsta¨mme mu¨ssen beru¨cksichtigt werden, da sie den
Beginn altersbedingter klinischer Symptome beeinflussen. Aufgrund der Vielzahl der derzeit verwendeten
Alterungsmodelle wird es kein universell gu¨ltiges Konzept geben ko¨nnen. Ein erho¨htes Bewusstsein fu¨r die
Problematik wird zu einer verbesserten und konsequenteren Haltung alternder Ma¨use fu¨hren, und die
Anwendung humaner Endpunkte wird dazu beitragen, die Zahl der Tiere zu verringern, die la¨nger gehalten
werden, als es wissenschaftlich gerechtfertigt ist.
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Resumen
Motivados por la prolongacio´n de la vida de los seres humanos, especialmente en las sociedades occidenta-
lizadas, y la necesidad de saber ma´s sobre el «envejecimiento saludable», los ratones envejecidos se esta´n
utilizando cada vez ma´s en la investigacio´n cientı´fica. Muchos departamentos e institutos que participan en
investigaciones sobre el envejecimiento han desarrollado sus propios sistemas para determinar los puntos de
intervencio´n para posibles mejoras e identificar criterios de valoracio´n humanos. Se esta´n utilizando varios
sistemas buenos, pero las variaciones entre ellos podrı´an contribuir a la escasa reproducibilidad de la ciencia
lograda. Trabajando con comunidades cientı´ficas y reguladoras en el Reino Unido, hemos revisado la
sintomatologı´a clı´nica observada en ratones envejecidos y hemos desarrollado recomendaciones para
mejorar el seguimiento, la evaluacio´n del comportamiento, la crı´a y las intervenciones veterinarias.
Nosotros defendemos que el plazo por defecto para un seguimiento reforzado sea los 15 meses de edad, a
menos que se disponga de informacio´n previa. Es importante destacar que el seguimiento reforzado no
deberı´a causar dan˜os adicionales a los animales. Cuando una cepa de rato´n esta´ bien definida, el inicio de
un seguimiento reforzado relacionado con la edad puede ser modificado en base al conocimiento de la
aparicio´n de un sı´ntoma clı´nico esperado relacionado con la edad. En los modelos progeroides en los que
se acelera el envejecimiento, puede ser necesario adelantar el seguimiento reforzado. Debe tenerse en
cuenta la informacio´n sobre la cepa de fondo, ya que influye en la aparicio´n de los signos clı´nicos relacionados
con la edad. La gama de modelos de envejecimiento que se utiliza actualmente significa que no habra´ una
solucio´n u´nica para todos los casos. Una mayor concienciacio´n de los problemas conducira´ a una crı´a ma´s
refinada y consistente de los ratones envejecidos, y la aplicacio´n de criterios de valoracio´n humanos ayudara´
a reducir el nu´mero de animales mantenidos durante ma´s tiempo del que esta´ cientı´ficamente justificado.
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